Literature DB >> 31463129

Nomogram predicting cancer-specific mortality in patients with esophageal adenocarcinoma: a competing risk analysis.

Xi-Xi Wu1, Ren-Pin Chen1, Rui-Cong Chen2, Hong-Peng Gong1, Bin-Feng Wang1, Ya-Ling Li1, Xin-Ran Lin1, Zhi-Ming Huang1.   

Abstract

BACKGROUND: Many factors are reported to be related to the prognosis of patients with esophageal adenocarcinoma (EAC), but few reliable and straightforward tools for clinicians to estimate individual mortalities have been developed. This study aimed to evaluate the probability of cancer-specific death for patients with EAC and to build nomograms for predicting long-term cancer-specific mortality and overall mortality for EAC patients.
METHODS: Between 2004 and 2013, a total of 20,623 patients were identified from the surveillance, epidemiology, and end results (SEER) database and randomly divided into training (N=14,436) and validation (N=6,187) cohorts. The cumulative incidence functions (CIFs) of EAC-specific death and other causes were evaluated at the 1st, 3rd, and 5th year after diagnosis. We integrated the significant prognostic factors to construct nomograms and subjected them to internal and external validation.
RESULTS: The CIFs of EAC-specific survival at 1, 3, and 5 years after diagnosis were 60.9%, 37.1%, and 31.3%, respectively. Predictors for cancer-specific mortality for EAC comprised tumor grade, tumor extension, the involvement of lymph nodes, distant metastasis, surgery of primary site, insurance recode, and marital status. For overall mortality, it also included the predictor of age at diagnosis. The nomograms were well-calibrated and had good discriminative ability with concordance indexes (c-indexes) of 0.733, 0.728, and 0.728 for 1-, 3- and 5-year prognosis prediction of EAC-specific mortality respectively, and 0.726, 0.720, 0.719 for 1-, 3-, and 5-year prognosis prediction of overall mortality respectively.
CONCLUSIONS: We proposed and validated the effective and convenient nomograms to predict cancer-specific mortality and the overall mortality for patients with EAC, which only require the basic information available in clinical practice.

Entities:  

Keywords:  Esophageal adenocarcinoma (EAC); mortality; nomogram; surveillance, epidemiology, and end results (SEER)

Year:  2019        PMID: 31463129      PMCID: PMC6687980          DOI: 10.21037/jtd.2019.07.56

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  33 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference.

Authors:  Zhongren Zhou; Yinglin Xia; Santhoshi Bandla; Vladislav Zakharov; Shaoping Wu; Jeffery Peters; Tony E Godfrey; Jun Sun
Journal:  Hum Pathol       Date:  2014-05-15       Impact factor: 3.466

3.  A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia.

Authors:  Christopher J Peters; Jonathan R E Rees; Richard H Hardwick; James S Hardwick; Sarah L Vowler; Chin-Ann J Ong; Chunsheng Zhang; Vicki Save; Maria O'Donovan; Doris Rassl; Derek Alderson; Carlos Caldas; Rebecca C Fitzgerald
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

4.  Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008).

Authors:  L N Mathieu; N F Kanarek; H-L Tsai; C M Rudin; M V Brock
Journal:  Dis Esophagus       Date:  2013-10-07       Impact factor: 3.429

5.  Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States.

Authors:  Putao Cen; Farzaneh Banki; Lee Cheng; Kamal Khalil; Xianglin L Du; Michael Fallon; Robert J Amato; Larry R Kaiser
Journal:  Ann Surg Oncol       Date:  2011-12-01       Impact factor: 5.344

6.  Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology.

Authors:  Claudia R Baquet; Patricia Commiskey; Kelly Mack; Stephen Meltzer; Shiraz I Mishra
Journal:  J Natl Med Assoc       Date:  2005-11       Impact factor: 1.798

7.  The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Authors:  Stephen B Edge; Carolyn C Compton
Journal:  Ann Surg Oncol       Date:  2010-06       Impact factor: 5.344

Review 8.  Obesity and cardiovascular disease.

Authors:  E Jokinen
Journal:  Minerva Pediatr       Date:  2014-11-11       Impact factor: 1.312

9.  The impact of radiation therapy sequencing on survival and cardiopulmonary mortality in the combined modality treatment of patients with esophageal cancer.

Authors:  Andrzej P Wojcieszynski; Abigail T Berman; Fei Wan; John P Plastaras; James M Metz; Nandita Mitra; Smith Apisarnthanarax
Journal:  Cancer       Date:  2013-02-07       Impact factor: 6.860

10.  Racial disparities in esophageal cancer outcomes.

Authors:  Sha'shonda L Revels; Arden M Morris; Rishindra M Reddy; Clifford Akateh; Sandra L Wong
Journal:  Ann Surg Oncol       Date:  2012-12-23       Impact factor: 5.344

View more
  4 in total

1.  Prognostic nomograms and risk-stratifying systems for predicting survival in patients with resected pT2-4aN0M0 esophageal carcinoma.

Authors:  Xiao-Meng Dou; Na Zhang; Yan-Yan Fang; Bo-Han Zhang; Jie-Jing Liao; Jing-Sheng Cai; Jin-Bo Li
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 3.005

2.  Lung Metastases in Newly Diagnosed Esophageal Cancer: A Population-Based Study.

Authors:  Jida Guo; Shengqiang Zhang; Huawei Li; Mohamed Osman Omar Hassan; Tong Lu; Jiaying Zhao; Linyou Zhang
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

3.  A Predicting Nomogram for Mortality in Patients With COVID-19.

Authors:  Deng Pan; Dandan Cheng; Yiwei Cao; Chuan Hu; Fenglin Zou; Wencheng Yu; Tao Xu
Journal:  Front Public Health       Date:  2020-08-11

4.  SHCBP1 Promotes the Progression of Esophageal Squamous Cell Carcinoma Via the TGFβ Pathway.

Authors:  Chunhong Ren; Zhengbo Zhou; Xiuzhen Wang; Xu Hua; Muping Zou; Xin Zhang
Journal:  Appl Immunohistochem Mol Morphol       Date:  2021-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.